No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection
Journal article, Peer reviewed
Published version
![Thumbnail](/bora-xmlui/bitstream/handle/11250/3022888/JGH%2bOpen%2b-%2b2022%2b-%2bHanevik%2b-%2bNo%2bdifference%2bin%2bserum%2blevels%2bof%2bB%25E2%2580%2590cell%2bactivating%2breceptor%2band%2bantibodies%2bagainst%2bcytolethal.pdf.jpg?sequence=6&isAllowed=y)
View/ Open
Date
2022Metadata
Show full item recordCollections
- Department of Clinical Science [2318]
- Registrations from Cristin [9791]
Original version
Journal of Gastroenterology and Hepatology Open (JGH Open). 2022, 6 (3), 185-188. 10.1002/jgh3.12724Abstract
Background and Aim
Functional gastrointestinal disorders (FGIDs) and chronic fatigue syndrome (CFS) frequently occur as comorbid conditions to each other. A shared etiology of these syndromes has been proposed because of their shared symptomatology and triggering by infections. Antibodies against the bacterial antigens cytolethal distending toxin B (CdtB) and flagellin have been proposed to be biomarkers of irritable bowel syndrome (IBS), especially diarrhea-predominant IBS (IBS-D). It is unknown if they may also be associated with comorbid conditions such as CFS. On the other hand, elevated level of B-cell activating factor (BAFF) has been associated with CFS and inflammatory bowel disease (IBD) and subjective food intolerance.
Methods
We evaluated serum levels of anti-flagellin and anti-CdtB using an in-house enzyme-linked immunosorbent assay (ELISA) and BAFF with a commercially available ELISA kit in a cohort of patients who developed fatigue syndromes and/or FGIDs after Giardia infection, by comparing them with healthy controls without these conditions.
Results
We did not find significant differences in circulating BAFF, anti-CdtB, or anti-flagellin antibody levels in these patient groups compared to healthy controls. Therefore, our results do not support a role for BAFF, anti-CdtB, or anti-flagellin antibodies as universal biomarkers for IBS or CFS.
Conclusion
BAFF, anti-CdtB, or anti-flagellin antibodies cannot be considered as universal biomarkers for IBS or CFS.